share_log

T2 Biosystems | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

T2 Biosystems | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)

T2 Biosystems | S-1/A：證券上市註冊聲明(修正)
美股sec公告 ·  05/07 05:30
牛牛AI助理已提取核心訊息
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed an amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on May 6, 2024. The amendment relates to a proposed offering of up to 3,322,259 shares of common stock, along with Pre-Funded Warrants and Series B-1 and Series B-2 Common Warrants to purchase an equal number of shares. The offering is on a 'reasonable best efforts' basis, with no minimum number of securities required to be sold. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'TTOO.' The offering aims to raise capital for working capital and general corporate purposes, including sales and marketing, manufacturing, and clinical development costs. The offering is expected to close on or about May 15, 2024, subject to customary closing conditions.
T2 Biosystems, a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, has filed an amendment to its Form S-1 registration statement with the Securities and Exchange Commission (SEC) on May 6, 2024. The amendment relates to a proposed offering of up to 3,322,259 shares of common stock, along with Pre-Funded Warrants and Series B-1 and Series B-2 Common Warrants to purchase an equal number of shares. The offering is on a 'reasonable best efforts' basis, with no minimum number of securities required to be sold. The company's common stock is listed on the Nasdaq Capital Market under the symbol 'TTOO.' The offering aims to raise capital for working capital and general corporate purposes, including sales and marketing, manufacturing, and clinical development costs. The offering is expected to close on or about May 15, 2024, subject to customary closing conditions.
T2 Biosystems是快速檢測誘發敗血症的病原體和抗生素耐藥基因領域的領導者，已於2024年5月6日向美國證券交易委員會（SEC）提交了其S-1表格註冊聲明的修正案。該修正案涉及擬發行最多3,322,259股普通股，以及預先籌資的認股權證以及B-1系列和B-2系列普通認股權證，以購買相同數量的股份。此次發行以 “合理的最大努力” 爲基礎，不要求出售最低數量的證券。該公司的普通股在納斯達克資本市場上市，股票代碼爲 “TTOO”。此次發行旨在爲營運資金和一般公司用途籌集資金，包括銷售和營銷、製造和臨床開發成本。此次發行預計將於2024年5月15日左右結束，但須遵守慣例成交條件。
T2 Biosystems是快速檢測誘發敗血症的病原體和抗生素耐藥基因領域的領導者，已於2024年5月6日向美國證券交易委員會（SEC）提交了其S-1表格註冊聲明的修正案。該修正案涉及擬發行最多3,322,259股普通股，以及預先籌資的認股權證以及B-1系列和B-2系列普通認股權證，以購買相同數量的股份。此次發行以 “合理的最大努力” 爲基礎，不要求出售最低數量的證券。該公司的普通股在納斯達克資本市場上市，股票代碼爲 “TTOO”。此次發行旨在爲營運資金和一般公司用途籌集資金，包括銷售和營銷、製造和臨床開發成本。此次發行預計將於2024年5月15日左右結束，但須遵守慣例成交條件。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

譯文內容由第三人軟體翻譯。


牛牛AI助手部分由第三方人工智慧模型基於資訊內容自動產生，只对除中国内地以外的地区提供。


以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。